NovoCure (NASDAQ: NVCR) director granted RSUs and 16,999 stock options

Rhea-AI Filing Summary

NovoCure Ltd director Jeryl L. Hilleman received new equity awards. On June 3, 2026, she was granted 11,610 Ordinary Shares as restricted stock units and 16,999 stock options with a $16.15 exercise price.

The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The stock options follow the same vesting schedule and will become fully exercisable at that time. After the share grant, Hilleman directly holds 25,471 Ordinary Shares, and the option grant represents her reported derivative position in this filing.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider HILLEMAN JERYL L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,999	$0.00	--
Grant/Award	Ordinary Shares	11,610	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,999 shares (Direct, null); Ordinary Shares — 25,471 shares (Direct, null)

Footnotes (1)

1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Key Figures

Restricted stock units granted: 11,610 Ordinary Shares Stock options granted: 16,999 options Option exercise price: $16.15 per share +2 more

5 metrics

Restricted stock units granted 11,610 Ordinary Shares Award to director on June 3, 2026

Stock options granted 16,999 options New option award on June 3, 2026

Option exercise price $16.15 per share Strike price for 16,999 stock options

Shares held after award 25,471 Ordinary Shares Director’s direct holdings after RSU grant

Award vesting trigger First anniversary or pre-2027 AGM Vesting schedule for RSUs and options

Key Terms

restricted stock units, stock option, exercise price, annual general meeting of shareholders, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"Stock Option (Right to Buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"Options to buy ordinary shares will fully vest and become exercisable"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual general meeting of shareholders regulatory

"the day immediately preceding the Company's 2027 annual general meeting of shareholders"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HILLEMAN JERYL L

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/03/2026		A		11,610	A	$0.00	25,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.15	06/03/2026		A		16,999		06/03/2027(2)	06/03/2036	Ordinary Shares	16,999	$0.00	16,999	D

Explanation of Responses:

1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Remarks:

	Steven Robbins, as attorney in fact for Hilleman, Jeryl L.	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did NovoCure (NVCR) director Jeryl Hilleman report?

Director Jeryl L. Hilleman reported two equity awards: a grant of 11,610 restricted Ordinary Shares and 16,999 stock options with a $16.15 exercise price, both dated June 3, 2026, reflecting routine director compensation rather than open-market trading.

How many NovoCure (NVCR) shares does Jeryl Hilleman hold after this Form 4?

Following the grant, Jeryl L. Hilleman directly holds 25,471 Ordinary Shares of NovoCure Ltd. This total reflects the new 11,610-share restricted stock unit award in addition to her prior holdings, as reported in the Form 4’s post-transaction share count field.

What are the terms of Jeryl Hilleman’s new NovoCure stock options?

Hilleman received 16,999 stock options to buy NovoCure Ordinary Shares at $16.15 per share. According to the filing, these options fully vest and become exercisable on the earlier of the first anniversary of the grant or the day before NovoCure’s 2027 annual meeting.

When do Jeryl Hilleman’s NovoCure restricted stock units vest?

The 11,610 restricted stock units granted to Jeryl Hilleman are scheduled to vest 100% on the earlier of two dates: the first anniversary of the June 3, 2026 grant or the day immediately preceding NovoCure’s annual general meeting of shareholders in 2027.

Does this NovoCure (NVCR) Form 4 show any insider share sales?

No sales are reported. The Form 4 shows two acquisition-type transactions, both coded “A” for awards: a restricted share grant and a stock option grant. There are no open-market purchases or sales indicated in the transaction summary fields.